Question 1

Is GLP-3 Reta a Real Research Compound?

Accepted Answer

GLP-3 Reta is a synthetic tri-agonist peptide studied in preclinical models and Phase 2 human trials. Researchers investigating metabolic pathways have documented its simultaneous activity at three receptor targets: GLP-1, GIP, and glucagon. Available at Spartan Peptides for in vitro laboratory research only.

Question 2

What Is GLP-3 Reta in Peptide Research?

Accepted Answer

The compound belongs to a class of incretin-based research peptides. It's not a naturally occurring hormone but a synthetic analog engineered to bind multiple receptor types at once. That triple-receptor profile is what makes it scientifically interesting and distinguishes it from earlier single or dual-agonist peptides. GLP-3 Reta was developed by Eli Lilly and studied under the designation LY3437943 before the research community adopted the shorthand "GLP-3 Reta." The name reflects its tri-receptor activity: GLP-1 agonism (like GLP-1 Sema research peptides), GIP agonism (like the GLP-2 Tirz second target), and glucagon receptor agonism as a third layer.

Question 3

Mechanism of Action Documented in Literature

Accepted Answer

Published research indicates GLP-3 Reta engages GLP-1 receptors to stimulate insulin secretion, GIP receptors to modulate insulin sensitivity, and glucagon receptors to influence hepatic glucose output and energy expenditure. The glucagon component is the key differentiator from GLP-2 Tirz. Glucagon receptor co-agonism is thought to increase resting energy expenditure in animal models. That mechanistic angle has driven considerable research interest. Worth noting: the compound's activity profile varies by tissue type and receptor density, so findings from in vitro models don't automatically translate to in vivo systems.

Question 4

Phase 2 Trial Results Overview

Accepted Answer

Jastreboff and colleagues published Phase 2 trial data in the New England Journal of Medicine in 2023, reporting substantial body weight reductions over 48 weeks at the highest study doses. The trial used a dose-escalation protocol across multiple cohorts, with endpoints focused on body weight, tolerability, and metabolic markers. As of 2024, Phase 3 trials are ongoing. GLP-3 Reta has not received FDA approval for any indication. All commercially available GLP-3 Reta is classified as a research compound for in vitro laboratory use only.

Question 5

How GLP-3 Reta Differs from GLP-1 Sema and GLP-2 Tirz

Accepted Answer

GLP-1 Sema is a GLP-1 mono-agonist. GLP-2 Tirz adds GIP agonism, making it a dual agonist. GLP-3 Reta adds a third layer with glucagon receptor activity. Each added receptor target changes the compound's pharmacodynamic profile in ways that preclinical researchers are still characterizing. The short version: more receptor targets means more complex mechanism and, in documented research models, potentially different metabolic effects. It's not simply "more of the same."

Question 6

Research Compound Availability at Spartan Peptides

Accepted Answer

Spartan Peptides supplies GLP-3 Reta as a lyophilized research compound with third-party HPLC and mass spectrometry verification. Each lot includes a certificate of analysis confirming sequence identity and purity. The compound is sold strictly for in vitro and preclinical laboratory research under applicable regulations.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

Is GLP-3 Reta? Frequently Asked Questions

Explore Full Research Index